Giá của Ceryvyn Therapeutics Ltd là bao nhiêu (OPT)

Giá của Ceryvyn Therapeutics Ltd (OPT) là $0.00846342

Mũ thị trường của Ceryvyn Therapeutics Ltd là gì (OPT)

Giới hạn thị trường của Ceryvyn Therapeutics Ltd (OPT) là $11.27M

Doanh thu Ceryvyn Therapeutics Ltd (OPT)

Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.

Năm	Doanh thu	Thay đổi
Không đủ dữ liệu cho ngày được cung cấp.

Năm

Doanh thu

Thay đổi

Không đủ dữ liệu cho ngày được cung cấp.

Công ty	Doanh thu	Chênh lệch doanh thu	Quốc gia
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Công ty

Doanh thu

Chênh lệch doanh thu

Quốc gia